- Home
- SMID vs TLSI Comparison
SMID vs TLSI Comparison
Compare SMID & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- TLSI
- Stock Information
- Founded
- SMID 1960
- TLSI 2010
- Country
- SMID United States
- TLSI United States
- Employees
- SMID N/A
- TLSI N/A
- Industry
- SMID Building Materials
- TLSI Medical Specialities
- Sector
- SMID Industrials
- TLSI Health Care
- Exchange
- SMID Nasdaq
- TLSI Nasdaq
- Market Cap
- SMID 166.5M
- TLSI 124.9M
- IPO Year
- SMID 1995
- TLSI N/A
- Fundamental
- Price
- SMID $39.43
- TLSI $4.69
- Analyst Decision
- SMID
- TLSI Strong Buy
- Analyst Count
- SMID 0
- TLSI 6
- Target Price
- SMID N/A
- TLSI $11.75
- AVG Volume (30 Days)
- SMID 22.1K
- TLSI 36.4K
- Earning Date
- SMID 11-14-2024
- TLSI 11-14-2024
- Dividend Yield
- SMID N/A
- TLSI N/A
- EPS Growth
- SMID 1025.92
- TLSI N/A
- EPS
- SMID 1.22
- TLSI N/A
- Revenue
- SMID $76,366,000.00
- TLSI $26,891,000.00
- Revenue This Year
- SMID N/A
- TLSI $60.96
- Revenue Next Year
- SMID N/A
- TLSI $53.65
- P/E Ratio
- SMID $31.93
- TLSI N/A
- Revenue Growth
- SMID 32.40
- TLSI 67.90
- 52 Week Low
- SMID $25.03
- TLSI $3.50
- 52 Week High
- SMID $51.96
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- SMID 37.98
- TLSI 51.68
- Support Level
- SMID $37.70
- TLSI $4.72
- Resistance Level
- SMID $40.20
- TLSI $5.32
- Average True Range (ATR)
- SMID 2.17
- TLSI 0.31
- MACD
- SMID -0.81
- TLSI 0.01
- Stochastic Oscillator
- SMID 17.40
- TLSI 47.52
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.